论文部分内容阅读
目的:比较分析131I治疗Graves甲状腺功能亢进症合并肝损害与131I联合保肝药物治疗Graves甲状腺功能亢进症合并肝损害的临床效果。方法:选取我院2011年至2014年12月期间接收治疗的62例Graves甲状腺功能亢进症合并肝损害患者作为研究分析对象。按照治疗方法将患者均分为对照组和研究组,对照组31例,研究组31例。对照组31例患者采用131I治疗,研究组31例患者采用131I联合保肝药物进行治疗,对比两组患者在相同治疗时间内的治疗效果。结果:治疗后1个月,两组患者治疗有效率无明显差异;治疗后3个月,研究组31例患者中,30例患者得到有效治疗,占总比74.19%,对照组组31例患者中15例患者得到有效治疗,占总比48.39%;两组数据比较,存在一定差异,具有统计学意义(P<0.05)。治疗后6个月,研究组中31例患者均得到有效治疗,治疗有效率为100%,对照组中30例患者得到有效治疗,治疗总有效率为96.77%。两组数据比较,存在一定差异,具有统计学意义(P>0.05)。结论:治疗Graves甲状腺功能亢进症合并肝损害就本文研究的两种治疗方式相比较,在最终所取得的治疗疗效上无显著差异,但在治疗时间上两组存在显著差异,采用131I联合保肝药物进行治疗Graves甲状腺功能亢进症合并肝损害,在保证治疗疗效的同时可缩短治疗时间。
Objective: To compare the clinical effects of 131I treatment of Graves hyperthyroidism with liver damage and 131I combined with hepatoprotective therapy on Graves’ hyperthyroidism with liver injury. Methods: Sixty-two Graves patients with hyperthyroidism and liver damage who received treatment during our hospital from 2011 to December 2014 were selected as research objects. According to the treatment method, the patients were divided into control group and study group, 31 cases in the control group and 31 cases in the study group. The control group of 31 patients treated with 131I, 31 patients in the study group were treated with 131I combined with hepatoprotective drugs, the two groups were compared in the same treatment time treatment. Results: At 1 month after treatment, there was no significant difference in the treatment efficiency between the two groups. At 3 months after treatment, 30 of the 31 patients in the study group were effectively treated, accounting for a total of 74.19% of the 31 patients in the control group 15 patients were effectively treated, accounting for a total of 48.39%; there was a certain difference between the two groups of data, with statistical significance (P <0.05). Six months after the treatment, 31 patients in the study group were treated effectively, and the effective rate was 100%. In the control group, 30 patients were effectively treated, and the total effective rate was 96.77%. There was a certain difference between the two groups of data, with statistical significance (P> 0.05). Conclusion: The treatment of Graves with hyperthyroidism combined with liver damage compared to the two treatment methods in this study, the final treatment achieved no significant difference, but in the treatment time there are significant differences between the two groups, the use of 131I liver Drugs to treat Graves Hyperthyroidism with liver damage, while ensuring the efficacy of treatment can shorten the treatment time.